GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.
How eCOA/ePRO is transforming clinical trials
Nov 25, 2024 · (Image: Getty/Spainter_vfx) Q: What trends do you see shaping eCOA/ePRO in the next year? SR: Personalization and adaptability are big ones.Patients want tailored experiences, so platforms will need to adapt to individual needs — whether that’s through language options, integration with personal devices, or customized notifications.
Novo Nordisk signs $285 million deal for a once-monthly Wegovy
Nov 7, 2024 · Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to its TransCon technology platform for the development, manufacturing and commercialization of Novo’s products in metabolic diseases, including obesity and type 2 diabetes.
GHO and Ampersand acquire CDMO Avid Bioservices for $1.1 billion
Nov 12, 2024 · GHO’s deal partner Ampersand Capital Partners is a middle-market private equity firm based in Boston, US, and Amsterdam, the Netherlands. For Ampersand, the Avid deal closely follows the acquisition of Nektar Therapeutics’ commercial-scale manufacturing facility and reagent supply business for a total of $90 million earlier in October.
CPHI 2024: Ardena expands bioanalytical and GMP services
At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch of a state-of-the-art nanomedicines GMP facility in Oss, Netherlands.
AbbVie acquires Nimble for oral peptides
Dec 17, 2024 · “The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.”
NorthStar launches radiopharmaceutical CDMO
Oct 24, 2024 · The increasing integration of medical radioisotopes with diagnostic and molecular imaging as well as the rise of personalized medicine is spurring the growth of the global market for these products, which was valued at $5.1 billion in 2022 and is expected to soar by 8.8% per year to $11.4 billion by 2032. NorthStar’s peers in the field include Nordion, Isotopen Technologien München (ITM ...
Adragos Pharma snaps up Baccinex to expand CDMO network
Nov 26, 2024 · Back in April this year, Raabe told Outsourcing Pharma that the company is on the lookout for strategic acquisitions with the mission to double or even triple its size in the coming years.. Adragos focuses its CDMO efforts on small molecule treatments, which are seeing a resurgence of interest even as biologics and cell and gene therapies generate big excitement in the biotech industry.
Interview: Adragos Pharma and the evolving world of outsourcing
Oct 4, 2024 · Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.